Haemonetics Corporation

NYSE HAE

Haemonetics Corporation Price to Book Ratio (P/B) on January 14, 2025: 4.36

Haemonetics Corporation Price to Book Ratio (P/B) is 4.36 on January 14, 2025, a -7.52% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Haemonetics Corporation 52-week high Price to Book Ratio (P/B) is 5.33 on May 14, 2024, which is 22.43% above the current Price to Book Ratio (P/B).
  • Haemonetics Corporation 52-week low Price to Book Ratio (P/B) is 3.88 on October 31, 2024, which is -10.88% below the current Price to Book Ratio (P/B).
  • Haemonetics Corporation average Price to Book Ratio (P/B) for the last 52 weeks is 4.50.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
NYSE: HAE

Haemonetics Corporation

CEO Mr. Christopher A. Simon
IPO Date May 10, 1991
Location United States
Headquarters 125 Summer Street
Employees 3,657
Sector Health Care
Industries
Description

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Similar companies

NVST

Envista Holdings Corp

USD 18.85

-0.74%

ATR

AptarGroup, Inc.

USD 154.61

0.47%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

TFX

Teleflex Incorporated

USD 179.17

0.35%

ATRC

AtriCure, Inc.

USD 34.69

0.87%

WST

West Pharmaceutical Services, Inc.

USD 328.96

-3.13%

RMD

ResMed Inc.

USD 228.83

-0.62%

MMSI

Merit Medical Systems, Inc.

USD 99.89

4.44%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

AKYA

Akoya Biosciences, Inc.

USD 2.60

-11.26%

StockViz Staff

January 15, 2025

Any question? Send us an email